Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Ad5-nCoV in People 6 Years and Older
NCT04566770Phase 2Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Safety indexes of adverse reactions, Immunogencity indexes of GMT and 1 more. Started Sep 2020; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04566770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566770.